Mouse OCTN2 is directly regulated by peroxisome proliferator-activated receptor α (PPAR α) via a PPRE located in the first intron

Gaiping Wen, Robert Ringseis, Klaus Eder

► To cite this version:

Gaiping Wen, Robert Ringseis, Klaus Eder. Mouse OCTN2 is directly regulated by peroxisome proliferator-activated receptor α (PPAR α) via a PPRE located in the first intron. *Biochemical Pharmacology*, 2009, 79 (5), pp.768. 10.1016/j.bcp.2009.10.002 . hal-00547634

HAL Id: hal-00547634

<https://hal.science/hal-00547634>

Submitted on 17 Dec 2010

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Accepted Manuscript

Title: Mouse OCTN2 is directly regulated by peroxisome proliferator-activated receptor α (PPAR α) via a PPRE located in the first intron

Authors: Gaiping Wen, Robert Ringseis, Klaus Eder

PII: S0006-2952(09)00854-5
DOI: doi:10.1016/j.bcp.2009.10.002
Reference: BCP 10348

To appear in: *BCP*

Received date: 4-8-2009
Revised date: 30-9-2009
Accepted date: 1-10-2009

Please cite this article as: Wen G, Ringseis R, Eder K, Mouse OCTN2 is directly regulated by peroxisome proliferator-activated receptor α (PPAR α) via a PPRE located in the first intron, *Biochemical Pharmacology* (2008), doi:10.1016/j.bcp.2009.10.002

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Mouse OCTN2 is directly regulated by peroxisome proliferator-activated
receptor α (PPAR α) via a PPRE located in the first intron**

Gaiping Wen¹, Robert Ringseis², Klaus Eder^{2*}

¹ Institute of Agricultural and Nutritional Sciences, Martin-Luther-Universität Halle-
Wittenberg, Von-Danckelmann-Platz 2, 06120 Halle (Saale), Germany

² Chair of Animal Nutrition, Center of Life and Food Sciences Weihenstephan, Technische
Universität München, Hochfeldweg 6, 85350 Freising, Germany

*Corresponding author: Prof. Dr. Klaus Eder, Chair of Animal Nutrition, Center of Life and
Food Sciences Weihenstephan, Technische Universität München, Hochfeldweg 6, 85350
Freising, Germany, phone: ++49-8161-712024, fax: ++49-8161-715367, e-mail:
k.eder@wzw.tum.de

Key words: peroxisome proliferator-activated receptor α (PPAR α), carnitine, novel organic
cation transporter 2 (OCTN2)

18 Recent studies provided strong evidence to suggest that OCTN2 is a direct target gene of
19 PPAR α . However, subsequent studies failed to demonstrate a functional peroxisome
20 proliferator response element (PPRE) in the promoter region of the OCTN2 gene. In the
21 present study we hypothesized that the OCTN2 gene is transcriptionally induced by PPAR α
22 via a functional PPRE located in the first intron. *In silico*-analysis of the first intron of mouse
23 OCTN2 revealed eleven putative PPRE with high similarity to the consensus PPRE. In
24 addition, reporter gene assays using a mouse OCTN2 intron reporter construct containing a
25 cluster of three partially overlapping PPRE (PPREint-1-8-10) revealed a marked response to
26 exogenous mouse PPAR α /RXR α and subsequent stimulation with PPAR α agonist WY-
27 14,643. Introduction of a selective mutation in either PPRE8 or PPRE10 in the PPREint-1-8-
28 10 reporter constructs caused a substantial loss of the responsiveness to PPAR α activation, but
29 a selective mutation in PPRE1 resulted in a complete loss of responsiveness to PPAR α
30 activation. Moreover, gel shift assays revealed binding of PPAR α /RXR α heterodimer to the
31 PPRE1 of mouse OCTN2 first intron. In conclusion, the present study shows that mouse
32 OCTN2 is a direct target gene of PPAR α and that transcriptional up-regulation of OCTN2 by
33 PPAR α is likely mediated via PPRE1 in its first intron.

34

INTRODUCTION

Peroxisome proliferator-activated receptor α (PPAR α) is a ligand-activated transcription factor that acts as an important regulator of lipid metabolism and energy homeostasis [1]. PPAR α is abundantly expressed in tissues with high rates of fatty acid oxidation such as liver, heart muscle, skeletal muscle, and kidney [2]. Transcriptional regulation of genes by PPAR α is mediated by binding of activated PPAR/retinoid X receptor (RXR) heterodimers to specific DNA sequences, called peroxisome proliferator response elements (PPRE), present in and around the promoter region of target genes [3-9], thereby stimulating the expression of those genes. Proteins encoded by these genes are involved in all aspects of fatty acid catabolism including cellular fatty acid uptake, intracellular fatty acid transport, fatty acid transport through the mitochondrial membrane, mitochondrial and peroxisomal fatty acid oxidation, ketogenesis as well as gluconeogenesis [2, 10]. PPAR α can be activated by both endogenous and synthetic ligands. Endogenous ligands of PPAR α are fatty acids and their derivatives (eicosanoids) [11, 12]. Endogenous ligand-activation of PPAR α is observed during fasting [10, 13], since free nonesterified fatty acids are released from adipose tissue and taken up into tissues at increased levels during this state. Consequently, in the liver, where PPAR α is most abundant, β -oxidation, ketogenesis as well as gluconeogenesis are dramatically increased as a consequence of the increased expression of PPAR α target genes [2, 10]. In addition to endogenous ligands, PPAR α is also activated by a heterogeneous group of synthetic compounds including WY-14,643 and the fibrate class of lipid lowering drugs (clofibrate, fenofibrate, bezafibrate, and gemfibrozil) [11, 12].

Many years ago it has been shown that starvation or treatment of rats with clofibrate increases the hepatic concentration of carnitine [14-17], which is an essential metabolite that is required for the β -oxidation of long-chain fatty acids in the mitochondrial matrix [18-20]. Hence, all tissues that use fatty acids as a fuel source require carnitine for normal function. The reason for the fasting- and clofibrate-induced increase in hepatic carnitine concentrations

60 became clear until recently we observed a marked, about 8-fold increase in the hepatic mRNA
 61 content of novel organic cation transporter 2 (OCTN2) in the liver of rats treated with the
 62 PPAR α agonist clofibrate [21]. OCTN2 and other OCTN isoforms (OCTN1 and OCTN3) are
 63 polyspecific transporters mediating the transport of several cations and l-carnitine [22, 23].
 64 Due to its high binding affinity for carnitine and its wide expression, OCTN2 is the
 65 physiologically most important carnitine transporter, operating for the reabsorption of
 66 carnitine from the urine as well as playing a major role in tissue distribution, and intracellular
 67 carnitine homeostasis [24, 25]. Subsequent studies in PPAR α knockout mice clearly revealed
 68 that transcriptional up-regulation of hepatic OCTN2 by fasting or treatment with PPAR α
 69 agonist WY-14,643 is dependent on PPAR α [26, 27]. In addition, studies in rats and pigs
 70 showed that OCTN2 is induced by fasting or clofibrate also in several other tissues with
 71 abundant PPAR α expression including kidney, skeletal muscle, heart, and small intestine [28-
 72 32]. Moreover, *in silico*-analysis of the promoter region of rat OCTN2 revealed several
 73 putative PPRE upstream of the transcription start site [28]. Collectively, these findings
 74 provided strong evidence to suggest that OCTN2 is a direct PPAR α target gene. Nevertheless,
 75 a more recent study employing reporter gene and gel shift assays revealed only a weak
 76 response of rat OCTN2 promoter gene constructs to fenofibrate or exogenous PPAR α and a
 77 weak binding of PPAR α to a proximal PPRE of the rat OCTN2 promoter, respectively [33].
 78 Based on these results it has been concluded that the contribution of this proximal PPRE to
 79 the OCTN2 promoter activity is low and that a more functional PPRE might be located in
 80 other regulatory regions of the OCTN2 gene [33]. Since regulatory elements are frequently
 81 observed in intronic regions [7, 8, 34] we hypothesized that the OCTN2 gene is
 82 transcriptionally induced by PPAR α via one or more functional PPRE located in intronic
 83 regions of the OCTN2 gene. In this study, we therefore performed *in silico*-analyses, reporter
 84 gene experiments and gel shift assays to investigate whether functional PPRE exist in intronic

regions of the mouse OCTN2 gene, and to get more insights into molecular mechanism underlying PPAR α -dependent up-regulation of the mouse OCTN2 gene.

MATERIALS AND METHODS

Chemicals

WY-14,643 was purchased from Sigma-Aldrich (Steinheim, Germany). RPMI1640 GlutaMax-1 medium, fetal calf serum (FCS) and gentamycin were from Invitrogen (Karsruhe, Germany).

Cell culture

The human hepatoma cell line HepG2 (DSMZ, Braunschweig, Germany), which is commonly used for transient transfection assays [35], was used in the present study. HepG2 cells were cultured in RPMI1640 GlutaMax-1 medium supplemented with 10% FCS and 0.05 mg/ml gentamycin. Cells were maintained at 37°C in a humidified atmosphere of 95 % air and 5 % CO₂. Medium was changed every 2 days. After reaching a confluence of 70-80%, the cells were seeded in 96-well culture plate at a density of 4 - 5 x 10⁴/well. The cells were used for transfection 24 h after reaching a confluence of 70 %.

In silico-analysis of mouse OCTN2 promoter and first intron

Using cDNA and genomic sequences from NCBI Genbank (Accession number BC031118 and CT571271) an approximately 2 kb fragment of mouse OCTN2 promoter from -1632 to +121 relative to transcription start site, and a 2 kb fragment of mouse OCTN2 first intron were scanned and analyzed for putative PPRE using NUBIScan (nuclear receptor binding site Scanner [36]).

Generation of mouse OCTN2 promoter reporter gene constructs

Five mouse OCTN2 promoter-truncation constructs were designed. The 1,753 bp promoter fragment pGL4.10-PPREprom-1753 (from -1632 to +121 relative to transcription start site) containing four identified putative PPRE was PCR amplified from mouse BAC clone RP23-303F24 (imaGene, Berlin, Germany). The generated PCR fragment with XhoI and HindIII restriction sites introduced at the 5' and 3' ends was subcloned into the XhoI and HindIII digested pGL4.10 [luc2] vector (Promega, Mannheim, Germany) upstream of the luciferase reporter gene. The OCTN2 promoter-truncation constructs pGL4.10-PPREprom-1043 (from -922 to +121) containing three putative PPRE, pGL4.10-PPREprom-750 (from -629 to +121) containing one putative PPRE, and pGL4.10-PPREprom-556 (from -435 to +121) containing no PPRE but a TATA box and three Sp1 sites, and pGL4.10-PPREprom-369 (from -248 to +121) containing no PPRE but a TATA box and one Sp1 site were PCR amplified from parental clone pGL4.10-PPREprom-1753 by using different 5'-primers flanking the putative PPRE and a common 3'-primer. The primer sequences and PCR product sizes are shown in Table 1. The generated PCR products containing two adapters of XhoI and HindIII site at the end were subcloned into the XhoI and HindIII digested pGL4.10 [luc2] vector upstream of the luciferase reporter gene. The cloned DNA fragments were sequenced to confirm the integrity of the constructs.

Generation of mouse OCTN2 first intron reporter gene constructs

Four DNA fragments containing the putative PPRE predicted from NUBIScan, namely PPREint-1-8-10 (280 bp from 1798 to 2079), PPREint-6-7 (179 bp from 1663 to 1843), PPREint-9-4 (504 bp from 1235 to 1739), and PPREint-2-3-5-11 (703 bp from 1 to 703) were PCR amplified from mouse BAC clone RP23-303F24 (imaGene) using specific primers. The primer sequences and PCR product sizes are shown in Table 1. The generated PCR products containing two adapters of KpnI and HindIII site in the end of the PCR fragments were

subcloned into the KpnI and HindIII digested pGL4.23 [luc2/minP] vector (Promega) which contains the minimal promoter minP followed by the luciferase reporter gene luc2 (Promega). After cloning, fragments were sequenced to confirm the integrity of the constructs.

Site-directed mutagenesis

Three mutation constructs of the OCTN2-PPREint-1-8-10 construct were prepared by selectively introducing a mutation in either PPRE1, PPRE8 or PPRE10 of the OCTN2 first intron with Site-Directed Mutagenesis kit (Stratagene Europe, Amsterdam, Netherlands) using the following oligonucleotides: PPREint-10mut (forward: 5'-GCCTCCTGCAAAATCTGCAGACCTGTAAGTAGGTG-3', reverse: 5'-CACCTACTTACAGGTCTGCAGATTTTGCAGGAGGC-3'), PPREint-8mut (forward: 5'-GCAAAACTGCTGTCCTGAAAGTAGGTGAAAGGGC-3', reverse: 5'-GCCCTTTCACCTACTTTCAGGACAGCAGTTTTTGC-3'), PPREint-1mut (forward: 5'-GACCTGTAAGTAGGTGTATGGGCATATAACTCTTA-3', reverse: 5'-TAAGAGTTATATGCCCATACACCTACTTACAGGTC-3'). The mutant constructs were controlled for the presence of the intended mutation and the absence of any unexpected mutations by DNS sequencing.

Transient transfection

HepG2 cells were transiently transfected with the generated reporter gene constructs and co-transfected with either mouse PPAR α expression plasmid (pCMX-mPPAR α) and mouse RXR α expression plasmid (pCMX-mRXR α) (both, generous gifts from R.M. Evans, Salk Institute for Biological Studies, San Diego, CA, USA) or empty vector (pCMX) using FuGENE 6 transfection reagent (Roche Diagnostics, Mannheim, Germany) according to the manufacturer's protocol. Cells were also co-transfected with pGL4.74 Renilla luciferase (Rluc) (encoding the renilla luciferase reporter gene; Promega), which was used as an internal

control reporter vector to normalize for differences in transfection efficiency. A 3X ACO-PPRE vector (containing three copies of consensus PPRE from the ACO promoter in front of a luciferase reporter gene; a generous gift from Dr. Sander Kersten, Nutrigenomics Consortium, Top Institute (TI) Food and Nutrition, Wageningen, Netherlands) and pGL4.10 (or pGL4.23) vector were used as positive and negative control vectors, respectively. Following transfection, cells were treated with either 50 μ M WY-14,643 to achieve activation of PPAR α or vehicle only (DMSO = control) for 24 h. Afterwards, cells were washed with phosphate-buffered saline and lysed with passive lysis buffer (Promega). Luciferase activities were determined with the Dual-Luciferase Reporter Assay System from Promega according to the manufacturer's instructions using a Mithras LB940 luminometer (Berthold Technologies, Bad Wildbad, Germany) as described recently in more detail [37].

Electrophoretic mobility shift assay (EMSA)

The mouse PPAR α and mouse RXR α proteins were generated from the expression vectors by *in vitro* transcription/translation using TNT[®] Quick Coupled Transcription/Translation Kit (Promega) according to the manufacturer's protocol. The following oligonucleotides were annealed with annealing buffer (10 mM Tris, 1 mM EDTA, 0.1 mM NaCl; pH 8.0): OCTN2-PPREint-1-8-10 (forward: 5'-TCGTAAGAGTTATATGCCCTTTCACCTACTTACAGGTCAGCAGTTTTTGCAGGAGG-3', reverse: 5'-CTTGCCTCCTGCAAAAAGTCTGACCTGTAAAGTAGGTGAAAGGGCATATAACTCTT-3'), for mutation OCTN2-PPREint-1-8-10mut (forward: 5'-TCGTAAGAGTTATATGCCCATACACCTACTTTCAGGACAGCAGATTTTGCAGGAGG-3', reverse: 5'-CTTGCCTCCTGCAAAAATCTGCTGTCCTGAAA GTAGGTGTATGGGCATATAACTCTT-3'), PPREcont-spec (rat-ACO-PPRE) as specific control and for competition (forward: 5'-TTCCCGAACGTGACCTTTGTCCTGGTCCCCTT TGAT C-3', reverse: 5'-AAAGGGGACCAGGACAAAGGTCACGTTCCGGGAAGATC-3'), PPREcont-non-spec as non-specific control (forward: 5'-GATCGTGACTCTTGTGGGGAT

189 ACTCTCTGACTCTA-3', reverse: 5'- AGCTTAGAGTCAGAGAGTATCCCCACAAGAG
 190 TCAC-3'). For OCTN2-PPREint-10 (forward: 5'-GACTGCCTCCTGCAAAAACTGCTGA
 191 CCTGTAAGTAG-3', reverse: 5'-AGCTCTACTTACAGGTCAGCAGTTTTTGCAGGAGG
 192 C-3'), for mutation OCTN2-PPREint-10mut (forward: 5'-GACTGCCTCCTGCAAAATCTG
 193 CAGACCTGTAAGTAG-3', reverse: 5'-AGCTCTACTTACAGGTCTGCAGATTTTGCAG
 194 GAGGC-3'). For OCTN2-PPREint-8 (forward: 5'-GACTAAAACTGCTGACCTGTAAGT
 195 AGGTGAAAGGG-3', reverse: 5'-AGCTCCCTTTTACCTACTTACAGGTCAGCAGTTTT
 196 T-3'), for mutation OCTN2-PPREint-8mut (forward: 5'-GACTAAAACTGCTGTCCTGAA
 197 AGTAGGTGAAAGGG-3', reverse: 5'-AGCTCCCTTTTACCTACTTTTCAGGACAGCAGT
 198 TTTT-3'). For OCTN2-PPREint-1 (forward: 5'-GACTCTGTAAGTAGGTGAAAGGGCAT
 199 ATAACTCTTA-3', reverse: 5'-AGCTTAAGAGTTATATGCCCTTTACCTACTTACAG-
 200 3'), for mutation OCTN2-PPREint-1mut (forward: 5'-GACTCTGTAAGTAGGTGTATGGG
 201 CATATAACTCTTA-3', reverse: 5'-AGCTTAAGAGTTATATGCCCATACACCTACTTA
 202 CAG-3'). After annealing 100 ng of double-stranded DNA-probes were labelled with 0.05
 203 mM DIG-ddUTP in 1X labelling buffer (0.2 M potassium cacodylate, 25 mM Tris-HCl, 0.25
 204 ng/ml bovine serum albumin; pH 6.6), 5 mM CoCl₂, 20 U/μl Terminal transferase (Roche)
 205 and incubated for 15 min at 37°C. Then 2 μl of each *in vitro* translated PPARα and RXRα
 206 proteins were incubated with 4 ng DIG-labelled probes and 5-, 50- and 100-fold molar excess
 207 of unlabelled specific probes for competition in 1 μg Poly d(I-C) and EMSA binding buffer
 208 (10 mM Tris-HCl, 120 mM KCl, 0.5 mM EDTA, 0.1 % Triton-X-100, 12.5 % glycerol, 0.2
 209 mM DTT) for 30 min at RT. The protein-DNA complexes were subjected to electrophoresis
 210 on 6 % native polyacrylamid gels, and transferred to a positive charged nylon membrane. The
 211 DIG-labelled DNA was detected by chemiluminescence using Anti-Digoxigenin-AP
 212 Conjugate and CSPD (both from Roche) according to the manufacturer's protocol (Roche),
 213 and a Bio-Imaging system (Biostep, Jahnsdorf, Germany).
 214

Statistical analysis

Numerical data were analyzed by one-way ANOVA using the Minitab Statistical Software (Minitab, State College, PA, USA). Differences of $P < 0.05$ were considered to be significant.

RESULTS

In silico-analysis of mouse OCTN2 for the existence of putative PPRE

To investigate, which genomic region could be responsible for the PPAR α -induced up-regulation of the mouse OCTN2 gene, we performed *in silico*-analysis of the promoter region and first intron of mouse OCTN2 for the existence of putative PPRE using NUBIScan software. According to this, four putative PPRE in the promoter region and eleven putative PPRE in the first intron were identified. The sequence alignment between the consensus PPRE AGGTCAAAGGTCA (termed DR-1: direct repeat 1) known from the literature [2] and the putative PPRE identified in the promoter and first intron of mouse OCTN2 showed high similarity (Table 2).

Transcriptional activity of putative PPRE in the proximal promoter of mouse OCTN2

To evaluate whether the putative PPRE identified in the mouse OCTN2 promoter region are responsible for PPAR α -mediated transactivation of OCTN2, we generated a series of plasmid constructs containing 5'-deleted fragments of mouse OCTN2 promoter upstream of a firefly luciferase reporter gene. These promoter reporter constructs were transiently transfected into HepG2 cells with co-transfection of either pCMX-mPPAR α and pCMX-mRXR α or empty vector (pCMX). As shown in Figure 1, we did not observe an increase of luciferase activity by WY-14,643 and/or co-expression of mouse PPAR α and RXR α in cells transfected with

either of these OCTN2 promoter reporter constructs indicating that the putative PPRE in the promoter region are probably not functional.

Transcriptional activity of putative PPRE in the first intron of mouse OCTN2

Next, we evaluated whether the putative PPRE identified in the first intron of mouse OCTN2 are responsible for PPAR α -mediated transactivation of OCTN2. As shown in Figure 2A and 2B, some of the eleven putative PPRE identified in the first intron of mouse OCTN2 overlapped each other: PPREint-1, PPREint-8 and PPREint-10 overlapped with each other, PPREint-6 overlapped with PPREint-7, and PPREint-5 overlapped with PPREint-3. PPRE2, PPRE4, PPRE9, and PPRE11 did not overlap with the other PPRE. Therefore, we generated different OCTN2 intron reporter gene constructs each containing a cluster of these partially overlapping PPRE, and transiently transfected these OCTN2 intron reporter constructs into HepG2 cells with co-transfection of either pCMX-mPPAR α and pCMX-mRXR α or empty vector (pCMX). As shown in Figure 2B, the luciferase activity did not increase in response to WY-14,643 and/or co-expression of mouse PPAR α /RXR α in cells transiently transfected with the reporter constructs PPREint-6-7, PPREint-9-4 and PPREint-2-3-5-11. However, in cells transiently transfected with the reporter construct PPREint-1-8-10 luciferase activity increased approximately 20-fold by co-expression of mouse PPAR α /RXR α and about 100-fold by co-expression of mouse PPAR α /RXR α and subsequent stimulation with WY-14,643 when compared to cells treated without WY-14,643 and without co-expression of mouse PPAR α /RXR α ($P < 0.05$). These findings indicated that PPRE1, PPRE8, and/or PPRE10 in the first intron at positions 1850 to 1869 are probably functional, and responsible for PPAR α -dependent regulation of mouse OCTN2.

To further explore which of PPRE1, PPRE8, and PPRE10 in the first intron of mouse OCTN2 are functional, we generated three mutant constructs from the PPREint-1-8-10 construct each containing a targeted mutation in either PPRE1, PPRE8 or PPRE10. As shown

in Figure 2C, cells transiently transfected with the mutant PPREint-1-8-10 constructs harboring a mutation in PPRE8 (PPREint-1-8-10-mut8) or PPRE10 (PPREint-1-8-10-mut10) showed an about 70 and 85 %, respectively, reduced luciferase activity in response to WY-14,643 and/or co-expression of mouse PPAR α /RXR α compared to cells transiently transfected with the wild-type PPREint-1-8-10 construct. However, transient transfection of the mutant PPREint-1-8-10 construct harboring a mutation in PPRE1 (PPREint-1-8-10-mut1) caused a complete loss of responsiveness to WY-14,643 and/or co-expression of mouse PPAR α /RXR α compared to transfection with the wild-type PPREint-1-8-10 construct.

***In vitro*-binding of PPAR α /RXR α heterodimer to PPREint-1-8-10 of mouse OCTN2**

To examine *in vitro*-binding of mouse PPAR α /RXR α heterodimer to the PPREint-1-8-10, we performed gel shift assays (EMSA) using *in vitro*-translated PPAR α and RXR α and DIG-labelled oligonucleotide corresponding to the PPREint-1-8-10 of mouse OCTN2. As shown in Figure 3, a strong DNA-protein complex was formed between the specific probe of rat ACO-PPRE and the *in vitro*-translated PPAR α /RXR α heterodimer as positive control (lane 2). DNA-protein complex formation between the oligonucleotide corresponding to the PPREint-1-8-10 of mouse OCTN2 and *in vitro*-translated PPAR α /RXR α heterodimer was also observed (lane 4). In addition, competition experiments using the oligonucleotide corresponding to the PPREint-1-8-10 and 5-, 50- 100-fold molar excess of unlabelled specific probe (rat ACO-PPRE) (lane 5, 6, and 7) were performed to test the specificity of PPAR α /RXR α binding. As demonstrated in Figure 3A, a weak complex was formed at 5-fold molar excess of unlabelled specific probe (lane 5), whereas this complex was absent at 50-fold (lane 6) and 100-fold (lane 7) molar excess of unlabelled specific probe being indicative of complete competition. No DNA-protein complex formation was observed between the mutant construct PPREint1-8-10-mut harboring a mutation in PPRE1, PPRE8, and PPRE10

and *in vitro*-translated PPAR α /RXR α heterodimer (lane 8). These results demonstrate that the PPAR α /RXR α heterodimer binds specifically to the PPREint-1-8-10 of mouse OCTN2.

To further evaluate which putative PPRE in the identified PPREint-10-8-1 cluster in the first intron of mouse OCTN2 is functional, we performed EMSA using individual oligonucleotides corresponding to either PPREint-10, PPREint-8 or PPREint-1 as well as their mutant counterparts PPREint-10mut, PPREint-8mut, and PPREint-1mut. As shown in Figure 4, a DNA-protein complex was formed between the oligonucleotide corresponding to the PPREint-1 of mouse OCTN2 and *in vitro*-translated PPAR α /RXR α heterodimer (lane 5). In addition, a DNA-protein complex was formed between the specific probe of rat ACO-PPRE as positive control and the *in vitro*-translated PPAR α /RXR α heterodimer (lane 7). However, no DNA-protein complex formation was observed between oligonucleotides corresponding to either PPREint-10 (lane 3) or PPREint-8 (lane 4) and *in vitro*-translated PPAR α /RXR α heterodimer. In addition, no DNA-protein complex was formed between oligonucleotides corresponding to the mutant PPREint-10 (lane 8), mutant PPREint-8 (lane 9), and mutant PPREint-1 (lane 10). These results demonstrate that the PPAR α /RXR α heterodimer binds specifically to the PPREint-1 of mouse OCTN2.

DISCUSSION

Recent studies from different groups provided strong evidence to suggest that OCTN2 is a direct target gene of PPAR α [21, 26, 27]. Direct PPAR α target genes are characterized by the presence of one or more functional PPRE located in and/or around their promoter region [3-9]. Although *in silico*-analysis of nuclear receptor binding sites revealed several putative PPRE upstream of the transcription start site of rat OCTN2 [28, 33], further studies employing promoter reporter gene and gel shift assays could not establish a major functional role of these putative PPRE [33]. This was evidenced by a low response to PPAR α activation of promoter reporter vectors containing these PPRE and a weak binding of PPAR α to these

PPRE [33]. Since transcription factor binding sites are also frequently observed in intronic regions of genes [6-8, 34], we hypothesized that the OCTN2 gene is transcriptionally induced by PPAR α via one or more functional PPRE located in the first intron.

The present study shows using NUBIScan analysis that the first 2 kb of the first intron of mouse OCTN2 contain eleven putative PPRE with high similarity to the conserved consensus PPRE, which is indicative of their importance for transcriptional regulation of the OCTN2 gene. The present study, moreover, demonstrates that three of these putative PPRE, namely PPRE1, PPRE8 and PPRE10, which show a partially overlapping alignment in the first intron of mouse OCTN2, are highly responsive to both, exogenous PPAR α /RXR α and PPAR α agonist WY-14,643. This could be shown in reporter gene assays using a reporter vector containing an approximately 200 bp fragment of the OCTN2 first intron including PPRE1, PPRE8 and PPRE10 (PPREint-1-8-10) in front of a luciferase reporter gene. The reporter activity of this construct could be dramatically increased by co-expression of exogenous mouse PPAR α /RXR α (20-fold compared to empty vector) and further markedly enhanced by the addition of WY-14,643 (5-fold compared to PPAR α /RXR α co-expression). The magnitude of induction of reporter activity by WY-14,643 is consistent with the increase in OCTN2 mRNA concentration by different PPAR α agonists in mouse and rat liver [21, 26-29]. Together with these recent findings, the present results indicate that the intronic region containing these PPRE is probably of great importance for PPAR α -dependent regulation of OCTN2. In contrast, transient transfection of other OCTN2 intron reporter vectors containing either PPRE9 and PPRE4 (PPREint-9-4), PPRE7 and PPRE6 (PPREint-7-6) or PPRE2, PPRE3, PPRE5, and PPRE11 (PPREint-2-3-5-11) did not result in any increase in reporter activity by either exogenous PPAR α /RXR α or WY-14,643. This suggests that these intronic regions of OCTN2 are probably of minor importance for PPAR α -dependent regulation of mouse OCTN2.

To further examine in more detail the functional role of the intronic region containing PPRE1, PPRE8, and PPRE10, we generated three different mutant PPREint-1-8-10 reporter constructs each harboring a selective mutation in either PPRE1, PPRE8 or PPRE10, and investigated their responsiveness to exogenous PPAR α /RXR α and/or WY-14,643. These experiments revealed that a selective mutation in either PPRE8 or PPRE10 caused a substantial loss of the responsiveness to PPAR α activation, but that a mutation in PPRE1 despite the presence of unmutated PPRE8 and PPRE10 resulted in a complete loss of responsiveness to both, exogenous PPAR α /RXR α and WY-14,643. These observations suggest that PPRE1 in the first intron of OCTN2 plays a decisive role in the PPAR α -dependent regulation of mouse OCTN2, whereas PPRE8 and PPRE10 are of less importance. However, the fact that a mutation in either PPRE8 or PPRE10 also caused a significant reduction of reporter activity in response to PPAR α activation (70 to 85 % reduction compared to PPREint-1-8-10 vector) indicates that a proper function of PPRE1 is also dependent on the nucleotide sequence adjacent to PPRE1. An explanation for this could be that mutations in the nucleotide sequence surrounding PPRE1 might impair proper binding of the PPAR α /RXR α complex including transcriptional co-activators to PPRE1 and, thereby, decrease transcriptional activity of this intronic region. In summary, these results suggest that the intronic region from PPRE1 to PPRE10 (positions 1850 to 1881 in mouse OCTN2 first intron) is of great importance for PPAR α -dependent regulation of mouse OCTN2. This assumption is also supported by the observation that the PPREint-1-8-10 sequence is highly conserved between species as demonstrated by the high similarity between mouse (positions 1850 to 1881), rat (positions 2019 to 2050), and human (positions 2271 to 2302) and to the consensus PPRE. The OCTN2 PPREint-1 showed a complete (100%) sequence homology between mouse, rat and human. This finding, therefore, suggests that regulation of the OCTN2 gene by PPAR α agonists is similar between mouse, rat and human.

To further explore the functional role of the PPREint-1-8-10 intronic sequence, we performed gel shift assays using *in vitro*-translated mouse PPAR α /RXR α proteins and an oligonucleotide representing PPREint-1-8-10. In the presence of PPAR α /RXR α proteins, a strong band appeared representing the DNA-PPAR α /RXR α complex which disappeared in the presence of an excess of unlabelled specific oligonucleotide. No band for the DNA-PPAR α /RXR α complex was observed when an oligonucleotide containing a mutated PPREint-1-8-10 sequence (PPREint-1-8-10-mut) was used. In addition, EMSA using individual oligonucleotides corresponding to either PPREint-10, PPREint-8 or PPREint-1 as well as their mutant counterparts PPREint-10mut, PPREint-8mut, and PPREint-1mut revealed a DNA-protein complex formation between the oligonucleotide corresponding to the PPREint-1 of mouse OCTN2 and *in vitro*-translated PPAR α /RXR α heterodimer. In contrast, no DNA-protein complex formation was observed when oligonucleotides corresponding to either wild-type or mutant PPREint-10 and PPREint-8 and mutant PPREint-1mut were used. Although we did not perform antibody supershift assays, these results strongly suggest that the PPAR α /RXR α heterodimer binds specifically to the PPREint-1 of mouse OCTN2. These findings again support our aforementioned assumption that the PPRE1 in the PPREint-1-8-10 cluster is of decisive importance for transcriptional regulation of mouse OCTN2. Moreover, these results provide further evidence to suggest that mouse OCTN2 is a direct PPAR α target gene with a functional PPREint-1 in its first intron.

The present study, moreover, shows that the mouse OCTN2 promoter region like the rat OCTN2 promoter [33] contains several PPRE with high similarity to the conserved consensus PPRE (AGGTCAAAGGTCA). However, these PPRE predicted from NUBIScan analysis are obviously not functional as demonstrated by reporter gene assays. Using serial 5'-deletion OCTN2 promoter constructs we clearly showed herein that the mouse OCTN2 promoter region is largely unresponsive to both, exogenous PPAR α /RXR α and treatment with

WY-14,643. These results indicate that the PPRE in the mouse OCTN2 promoter are probably not involved in the induction of the OCTN2 gene by PPAR α .

We have recently postulated that up-regulation of OCTN2 by PPAR α activation is a means to supply cells with sufficient carnitine required for transport of excessive amounts of fatty acids into the mitochondrion, and therefore plays an important role in the adaptive response of cells to PPAR α activation [21]. Since OCTN2 is polyspecific and able to bind other monovalent cations and various drugs such as verapamil, spironolactone or mildronate [38-43], up-regulation of OCTN2 by PPAR α activation in tissues due to treatment with pharmacological PPAR α activators may be not only relevant with respect to carnitine homeostasis but also to tissue distribution and intestinal absorption of various other compounds. In fact, we have recently observed that treatment of rats with PPAR α activator clofibrate increases intestinal absorption of dietary carnitine [29]. It is, therefore, not unlikely that fibrates and other PPAR α agonists influence intestinal absorption and tissue distribution of such compounds.

In conclusion, the present study shows using reporter gene and gel shift assays that mouse OCTN2 is a direct target gene of PPAR α and that transcriptional up-regulation of OCTN2 by PPAR α is likely mediated via PPRE1 in its first intron. Although we could demonstrate binding of PPAR α /RXR α heterodimer to this intronic PPRE1, we cannot exclude the possibility that transactivation of the OCTN2 gene in response to PPAR α activation is also mediated by additional functional PPRE in other intronic regions or by binding of other transcription factors to the promoter region. For instance, Mandard et al. [8] reported regulation of the PPAR target gene glycogen synthase 2 by hepatic nuclear factor 4 α (HNF4 α) via a HNF4 α response element in the promoter and by PPAR α via a PPRE in the first intron. Since HNF4 α is known to recognize DR-1 sequences like PPRE as well, it may be speculated that the “non-functional” PPRE identified in the mouse OCTN2 promoter region are probably also occupied by other transcription factors such as HNF4 α . Thus, future studies have to

demonstrate whether HNF4 α might induce the OCTN2 gene via a DR-1 motif in its promoter region.

REFERENCES

- 1 Desvergne, B. and Wahli, W. (1999) Peroxisome proliferator-activated receptors: Nuclear control of metabolism. *Endocr. Rev.* **20**, 649-688
- 2 Mandard, S., Müller, M. and Kersten, S. (2004) Peroxisome proliferator receptor α target genes. *Cell. Mol. Life Sci.* **61**, 393-416
- 3 Schoonjans, K., Martin, G., Staels, B. and Auwerx, J. (1997) Peroxisome proliferator-activated receptors, orphans with ligands and functions. *Curr. Opin. Lipidol.* **8**, 159-166
- 4 Tan, N.S., Michalik, L., Desvergne, B. and Wahli, W. (2005) Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes. *J. Steroid Biochem. Mol. Biol.* **93**, 99-105
- 5 Qi, C., Zhu, Y. and Reddy, J.K. (2000) Peroxisome proliferator-activated receptors, coactivators, and downstream targets. *Cell Biochem. Biophys.* **32**, 187-204
- 6 Hansmannel, F., Clémencet, M.C., Le Jossic-Corcos, C., Osumi, T., Latruffe, N. and Nicolas-Francis, V. (2003) Functional characterization of a peroxisome proliferator response-element located in the intron 3 of rat peroxisomal thiolase B gene. *Biochem. Biophys. Res. Commun.* **311**, 149-155
- 7 Helledie, T., Grøntved, L., Jensen, S.S., Kiilerich, P., Rietveld, L., Albrechtsen, T., Boysen, M.S., Nøhr, J., Larsen, L.K., Fleckner, J. et al. (2002) The gene encoding the Acyl-CoA-binding protein is activated by peroxisome proliferator-activated receptor gamma through an intronic response element functionally conserved between humans and rodents. *J. Biol. Chem.* **277**, 26821-26830

- 8 Mandard, S., Stienstra, R., Escher, P., Tan, N.S., Kim, I., Gonzalez, F.J., Wahli, W.,
Desvergne, B., Müller, M. and Kersten, S. (2007) Glycogen synthase 2 is a novel
target gene of peroxisome proliferator-activated receptors. *Cell. Mol. Life Sci.* **64**,
1145-1157
- 9 Gutgesell, A., Wen, G., König, B., Koch, A., Spielmann, J., Stangl, G.I., Eder, K. and
Ringseis, R. (2009) Mouse carnitine-acylcarnitine translocase (CACT) is
transcriptionally regulated by PPAR α and PPAR δ in liver cells. *Biochim. Biophys.*
Acta (in press)
- 10 Kersten, S., Seydoux, J., Peters, J.M., Gonzalez, F.J., Desvergne, B. and Wahli, W.
(1999) Peroxisome proliferator-activated receptor α mediates the adaptive response to
fasting. *J. Clin. Invest.* **103**, 1489-1498
- 11 Forman, B.M., Chen, J. and Evans, R.M. (1997) Hypolipidemic drugs,
polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-
activated receptors α and δ . *Proc. Natl. Acad. Sci. U. S. A.* **94**, 4312-4317
- 12 Krey, G., Braissant, O., L'Horsset, F., Kalkhoven, E., Perroud, M., Parker, M.G. and
Wahli, W. (1997) Fatty acids, eicosanoids, and hypolipidemic agents identified as
ligands of peroxisome proliferator-activated receptors by coactivator-dependent
receptor ligand assay. *Mol. Endocrinol.* **11**, 779-791
- 13 Leone, T.C., Weinheimer, C.J. and Kelly, D.P. (1999) A critical role for the
peroxisome proliferator-activated receptor α (PPAR α) in the cellular fasting response:
the PPAR α -null mouse as a model of fatty acid oxidation disorders. *Proc. Natl. Acad.*
Sci. U. S. A. **96**, 7473-7478
- 14 McGarry, J.D., Robles-Valdes, C. and Foster, D.W. (1975) Role of carnitine in hepatic
ketogenesis. *Proc. Natl. Acad. Sci. U. S. A.* **72**, 4385-4388
- 15 Brass, E.P. and Hoppel CL. (1978) Carnitine metabolism in the fasting rat. *J. Biol.*
Chem. **253**, 2688-2693

- 16 Paul, H.S. and Adibi, S.A. (1979) Paradoxical effects of clofibrate on liver and muscle metabolism in rats. Induction of myotonia and alteration of fatty acid and glucose oxidation. *J. Clin. Invest.* **64**, 405-412
- 17 Paul, H.S., Gleditsch, C.E. and Adibi, S.A. (1986) Mechanism of increased hepatic concentration of carnitine by clofibrate. *Am. J. Physiol.* **251**, E311-E315
- 18 McGarry, J.D. and Brown, N.F. (1997) The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. *Eur. J. Biochem.* **244**, 1-14
- 19 Brass, E.P. (2002) Pivalate-generating prodrugs and carnitine homeostasis in man. *Pharmacol. Rev.* **54**, 589-598
- 20 Steiber, A., Kerner, J. and Hoppel, C.L. (2004) Carnitine: a nutritional, biosynthetic, and functional perspective. *Mol. Asp. Med.* **25**, 455-473
- 21 Luci, S., Geissler, S., König, B., Koch, A., Stangl, G.I., Hirche, F. and Eder, K. (2006) PPAR α agonists up-regulate organic cation transporters in rat liver cells. *Biochem. Biophys. Res. Commun.* **350**, 704-708
- 22 Ohashi, R., Tamai, I., Yabuuchi, H., Nezu, J.I., Oku, A., Sai, Y., Shimane, M. and Tsuji, A. (1999) Na⁺-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. *J. Pharmacol. Exp. Ther.* **291**, 778-784
- 23 Ohashi, R., Tamai, I., Nezu, J.I., Nikaido, H., Hashimoto, N., Oku, A., Sai, Y., Shimane, M. and Tsuji, A. (2001) Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2. *Mol. Pharmacol.* **59**, 358-366
- 24 Tamai, I., Ohashi, R., Nezu, J., Yabuuchi, H., Oku, A., Shimane, M., Sai, Y. and Tsuji, A. (1998) Molecular and functional identification of sodium iondependent, high affinity human carnitine transporter OCTN2. *J. Biol. Chem.* **273**, 20378-20382

- 496 25 Tamai, I., Ohashi, R., Nezu, J.I., Sai, Y., Kobayashi, D., Oku, A., Shimane, M. and
 497 Tsuji, A. (2000) Molecular and functional characterization of organic cation/carnitine
 498 transporter family in mice. *J. Biol. Chem.* **275**, 40064-40072
- 499 26 van Vlies, N., Ferdinandusse, S., Turkenburg, M., Wanders, R.J. and Vaz, F.M. (2007)
 500 PPAR α -activation results in enhanced carnitine biosynthesis and OCTN2-mediated
 501 hepatic carnitine accumulation. *Biochim. Biophys. Acta* **1767**, 1134-1142
- 502 27 Koch, A., König, B., Stangl, G.I. and Eder, K. (2008) PPAR α mediates transcriptional
 503 upregulation of novel organic cation transporters-2 and -3 and enzymes involved in
 504 hepatic carnitine synthesis. *Exp. Biol. Med. (Maywood)* **233**, 356-365
- 505 28 Ringseis, R., Pösel, S., Hirche, F. and Eder, K. (2007) Treatment with
 506 pharmacological peroxisome proliferator-activated receptor alpha agonist clofibrate
 507 causes upregulation of organic cation transporter 2 in liver and small intestine of rats.
 508 *Pharmacol. Res.* **56**, 175-183
- 509 29 Ringseis, R., Lüdi, S., Hirche, F. and Eder K. (2008) Treatment with pharmacological
 510 peroxisome proliferator-activated receptor alpha agonist clofibrate increases intestinal
 511 carnitine absorption in rats. *Pharmacol. Res.* **58**, 58-64
- 512 30 Ringseis, R., Luci, S., Spielmann, J., Kluge, H., Fischer, M., Geissler, S., Wen, G.,
 513 Hirche, F. and Eder, K. (2008) Clofibrate treatment up-regulates novel organic cation
 514 transporter (OCTN)-2 in tissues of pigs as a model of non-proliferating species. *Eur. J.*
 515 *Pharmacol.* **583**, 11-17
- 516 31 Ringseis, R., Wege, N., Wen, G., Rauer, C., Hirche, F., Kluge, H. and Eder K. (2008)
 517 Carnitine synthesis and uptake into cells are stimulated by fasting in pigs as a model of
 518 nonproliferating species. *J. Nutr. Biochem.* [Epub ahead of print]
- 519 32 Luci, S., Hirche, F. and Eder K. (2008) Fasting and caloric restriction increases
 520 mRNA concentrations of novel organic cation transporter-2 and carnitine
 521 concentrations in rat tissues. *Ann. Nutr. Metab.* **52**, 58-67

- 33 Maeda, T., Wakasawa, T., Funabashi, M., Fukushi, A., Fujita, M., Motojima, K. and
Tamai, I. (2008) Regulation of Octn2 transporter (SLC22A5) by peroxisome
proliferator activated receptor α . *Biol. Pharm. Bull.* **31**, 1230-1236
- 34 Schupp, M., Lefterova, M.I., Janke, J., Leitner, K., Cristancho, A.G., Mullican, S.E.,
Qatanani, M., Szwegold, N., Steger, D.J., Curtin, J.C. et al. (2009) Retinol saturase
promotes adipogenesis and is downregulated in obesity. *Proc. Natl. Acad. Sci. U. S. A.*
106, 1105-1110.
- 35 Kast-Woelbern, H.R., Dana, S.L., Cesario, R.M., Sun, L., de Grandpre, L.Y., Brooks,
M.E., Osburn, D.L., Reifel-Miller, A., Klausning, K. and Leibowitz, M.D. (2004)
Rosiglitazone induction of Insig-1 in white adipose tissue reveals a novel interplay of
peroxisome proliferator-activated receptor gamma and sterol regulatory element-
binding protein in the regulation of adipogenesis. *J. Biol. Chem.* **279**, 23908-23915
- 36 Podvinec, M., Kaufmann, M.R., Handschin, C. and Meyer, U.A. (2002) NUBIScan,
an in silico approach for prediction of nuclear receptor response elements. *Mol.*
Endocrinol. **16**, 1269-1279
- 37 Ringseis, R., König, B., Leuner, B., Schubert, S., Nass, N., Stangl, G. and Eder, K.
(2006) LDL receptor gene transcription is selectively induced by t10c12-CLA but not
by c9t11-CLA in the human hepatoma cell line HepG2. *Biochim. Biophys. Acta* **1761**,
1235-1243
- 38 Wu, X., Huang, W., Prasad, P.D., Seth, P., Rajan, D.P., Leibach, F.H., Chen, J.,
Conway, S.J. and Ganapathy, V. (1999) Functional characteristics and tissue
distribution pattern of organic cation transporter 2 (OCTN2), an organic
cation/carnitine transporter. *J. Pharmacol. Exp. Ther.* **290**, 1482-1492
- 39 Koepsell, H. and Endou, H. (2004) The SLC22 drug transporter family. *Pflugers Arch.*
447, 666-676

- 547 40 Lahjouji, K., Elimrani, I., Lafond, J., Leduc, L., Qureshi, I.A. and Mitchell, G.A.
 548 (2004) L-Carnitine transport in human placental brush-border membranes is mediated
 549 by the sodium-dependent organic cation transporter OCTN2. *Am. J. Physiol. Cell*
 550 *Physiol.* **287**, C263-C269
- 551 41 Grube, M., Meyer zu Schwabedissen, H.E., Prager, D., Haney, J., Möritz, K.U.,
 552 Meissner, K., Roskopf, D., Eckel, L., Böhm, M., Jedlitschky, G. and Kroemer, H.K.
 553 (2006) Uptake of cardiovascular drugs into the human heart: expression, regulation,
 554 and function of the carnitine transporter OCTN2 (SLC22A5). *Circulation* **113**, 1114-
 555 1122
- 556 42 Hirano, T., Yasuda, S., Osaka, Y., Kobayashi, M., Itagaki, S. and Iseki, K. (2006)
 557 Mechanism of the inhibitory effect of zwitterionic drugs (levofloxacin and
 558 grepafloxacin) on carnitine transporter (OCTN2) in Caco-2 cells. *Biochim. Biophys.*
 559 *Acta* **1758**, 1743-1750
- 560 43 Kato, Y., Sugiura, M., Sugiura, T., Wakayama, T., Kubo, Y., Kobayashi, D., Sai, Y.,
 561 Tamai, I., Iseki, S. and Tsuji, A. (2006) Organic cation/carnitine transporter OCTN2
 562 (Slc22a5) is responsible for carnitine transport across apical membranes of small
 563 intestinal epithelial cells in mouse. *Mol. Pharmacol.* **70**, 829-837

564 **Table 1** Oligonucleotides used for PCR amplification of promoter region and first
 565 intron of mouse OCTN2

Oligonucleotide name	Oligonucleotide sequence (5' to 3')	PCR product size (bp)
PPREprom-F	ATAAAGCTTGCCGTCCTCAGCCTCCCAC	
PPREprom-369R	ATACTCGAGGTTCTGAAGCCCGGTTTCAGCC	369
PPREprom-556R	ATACTCGAGCTGCTCCAGGAAGTGTCTG	556
PPREprom-750R	ATACTCGAGCTGTCGTTGTCAATGAGACTC	750
PPREprom-1043R	ATACTCGAGCACCTTTCTCATCACCAGTCT	1043
PPREprom-1753R	ATACTCGAGCAGCATTCTCTCTCCTGGCTT	1753
PPREint-1810F	ATAGGTACCCAATGGATCTGGATGCTATTG	
PPREint-1810R	ATAAAGCTTGCTGACTAGCTGCAGTTGTC	280
PPREint-67F	ATAGGTACCCTTCACTGTCGTCTTGCTCG	
PPREint-67R	ATAAAGCTTCTCTTACGAAACTGCTAAGATA	179
PPREint-94F	ATAGGTACCCTGGTCAGTGATGGAGCACA	
PPREint-94R	ATAAAGCTTTTGCTGATCAGCCAGCCTCT	504
PPREint-23511F	ATAGGTACCGTAGGTGACAGCCCCCCT	
PPREint-23511R	ATAAAGCTTCCAGCAGAGTGACTGAGAAAT	703

566

566 **Table 2** Alignment of consensus PPRE sequence with sequences of predicted putative
 567 PPRE as obtained from *in silico*-analysis of the promoter region and first intron
 568 of mouse OCTN2 using NUBIScan software

PPRE denomination	Position	Sequence
Consensus PPRE	-	<u>AGGTCA</u> A <u>AGGTCA</u>
<i>Putative PPRE in promoter region of mouse OCTN2</i>		
PPRE1 [#]	-1389 to -1401 (+)*	AGGGAA a GGGTGA
PPRE2	-749 to -761 (-)	AAGGCA t AGGGCA
PPRE3	-761 to -773 (-)	AGCTCA c AGGCCC
PPRE4	-459 to -471 (-)	AGGTCA a AGCTAC
<i>Putative PPRE in intron 1 of mouse OCTN2</i>		
PPRE1	1850 to 1862 (-)	AGGTGA a AGGGCA
PPRE2	226 to 238 (-)	GGGTCT c AGGGCA
PPRE3	302 to 314 (+)	AGAGAA g AGGCCA
PPRE4	1616 to 1628 (-)	AGGTCA g GGTAAA
PPRE5	309 to 321 (+)	AGGCCA c AGTTTT
PPRE6	1749 to 1761 (-)	AGGTCA a AAAGAA
PPRE7	1755 to 1768 (-)	ATGCAG t AGGTCA
PPRE8	1862 to 1874 (+)	TACTTA c AGGTCA
PPRE9	1438 to 1450 (+)	AGTCCA c AGAGAA
PPRE10	1869 to 1881 (+)	AGGTCA g CAGTTT
PPRE11	582 to 594 (+)	AGATCA c TGGAGA

569 [#] PPRE are numbered by ascending p value as obtained from *in silico*-analysis for putative
 570 PPRE of promoter region and first intron of mouse OCTN2 using NUBIScan software.

571 * The direction of the PPRE is indicated in brackets with “+” or “-”.

572

LEGENDS TO FIGURES

Figure 1 Effect of exogenous mouse PPAR α /RXR α and PPAR α ligand WY-14,643 on transcriptional activity of OCTN2 promoter-truncation reporter constructs

HepG2 cells were transiently transfected with serial 5'-deletion OCTN2 promoter reporter constructs, and a renilla luciferase expression vector for normalization. Cells were also co-transfected with or without (empty vector) expression vectors for mouse PPAR α and RXR α . After transfection, cells were stimulated or not with 50 μ M of WY-14,643 for 24 h. Afterwards, cells were lysed, and luciferase activities of the OCTN2 promoter-truncation reporter vectors and the renilla luciferase expression vector determined by dual luciferase assay. Results represent means $\pm$ SEM for one out of three independent experiments each performed in triplicate.

Figure 2 Effect of exogenous mouse PPAR α /RXR α and PPAR α ligand WY-14,643 on transcriptional activity of OCTN2 intron reporter constructs

(A) Sequence alignment of consensus PPRe with the PPReint-1-8-10 sequence found in OCTN2 first intron of mouse (nucleotide positions from 1850 to 1881) and rat (nucleotide positions from 2019 to 2050). Matching nucleotides between mouse, rat and human are shown by asterisks. Sequence of putative PPReint-1 and PPReint-8 overlapped with one nucleotide, and putative PPReint-8 and PPReint-10 overlapped with six nucleotides. The mutated nucleotides introduced in the OCTN2 intron reporter constructs for mutation analysis are underlined. (B) HepG2 cells were transiently transfected with different OCTN2 intron reporter constructs, and a renilla luciferase expression vector for normalization. Cells were also co-transfected with or without (empty vector) expression vectors for mouse PPAR α and RXR α . After transfection, cells were stimulated or not with 50 μ M of WY-14,643 for 24 h.

Afterwards, cells were lysed, and luciferase activities of the OCTN2 promoter-truncation reporter vectors and the renilla luciferase expression vector determined by dual luciferase assay. Results represent means $\pm$ SEM for one out of three independent experiments each performed in triplicate. (C) HepG2 cells were transiently transfected with mutant constructs from OCTN2-PPREint-1-8-10 construct each containing a targeted mutation in either PPRE1, PPRE8 or PPRE10, and a renilla luciferase expression vector for normalization. Cells were also co-transfected with or without (empty vector) expression vectors for mouse PPAR α and RXR α . After transfection, cells were stimulated or not with 50 μ M of WY-14,643 for 24 h. Afterwards, cells were lysed, and luciferase activities of the OCTN2 promoter-truncation reporter vectors and the renilla luciferase expression vector determined by dual luciferase assay. Results represent means $\pm$ SEM for one out of three independent experiments each performed in triplicate.

Figure 3 Binding of *in vitro*-translated mouse PPAR α /RXR α to the PPREint-1-8-10 of mouse OCTN2 intron

EMSA was performed using *in vitro*-translated mouse PPAR α /RXR α and DIG-labelled oligonucleotide corresponding to either wild-type or mutated PPREint-1-8-10. Fold molar excess of unlabelled specific probe for competition (rat-ACO-PPRE) is indicated. The use of DIG-labelled specific probe (corresponding to rat-ACO-PPRE oligonucleotides) and non-specific probe (corresponding to random oligonucleotides of OCTN2 intron 1) is also indicated.

Figure 4 Binding of *in vitro*-translated mouse PPAR α /RXR α to the PPREint-1 of mouse OCTN2 intron

EMSA was performed using *in vitro*-translated mouse PPAR α /RXR α and DIG-labelled oligonucleotides corresponding to either PPREint-10, PPREint-8 or PPREint-1 as well as their

624 mutant counterparts PPREint-10mut, PPREint-8mut, and PPREint-1mut. The use of DIG-
625 labelled specific probe (corresponding to rat-ACO-PPRE oligonucleotides) and non-specific
626 probe (corresponding to random oligonucleotides of OCTN2 intron 1) is also indicated.

Consensus PPRE

ACTGGAACTGGAAGGTCAaAGGTCAAGGTCAaAGGTCA

mOCTN2-PPREint-1-8-10AAGAGTTATATGCCCTtTCACCTACTTAcAGGTCAgCAGTTTTTGCAGG-AGG

rOCTN2-PPREintAAGAGTTATATGCCCTtTCACCTACTTAcAGGTCAgCAGTCTTTGCAGG-AGG

hOCTN2-PPREintAGGAGTTATGTGCCCTtTCACCTACTTAAtATGTTGtCAGTCTTTGCAGGGAGG

* ***** ***** * ** **** ***** **

mOCTN2-PPREint-1: TGCCCTtTCACCT

mOCTN2-PPREint-1mut: TGCCCAtACACCT

mOCTN2-PPREint-8: TACTTAcAGGTCA

mOCTN2-PPREint-8mut: TACTTTcAGGACA

mOCTN2-PPREint-10: AGGTCAgCAGTTT

mOCTN2-PPREint-10mut: AGGACAgCAGATT

Figure 2A

Figure 2C

	mOCTN2-PPRE-					PPREcont-		mOCTN2-PPRE-		
	int-1	int-1	int-10	int-8	int-1	non-spec.	spec.	int-10mut	int-8mut	int-1mut
mPPAR α	+	-	+	+	+	+	+	+	+	+
mRXR α	-	+	+	+	+	+	+	+	+	+